The Study of Efficacy and Safety of Sebclair® in Mild to Moderate Degree Seborrheic Dermatitis (SD)

Phase 4

Recruiting

• Conditions: mild to moderated seborrheic dermatitis; seborrheic dermatitis; sebclair

• Registration Number: TCTR20170206007
• Lead Sponsor: A. Menarini (Thailand) Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-02-06
• Study Completion: 2017-07-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

18-60 years with mild to moderate seborrheic dermatitis

Exclusion Criteria

those with underlying medical problems or with current medications taken.
those who stop using topical medications not less than two weeks or systemic medications not less then 4 weeks
Pregnancy or lactating status

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
total number of day of steroid used 6 months mean

Secondary Outcome Measures

Name	Time	Method
side effect of sebclair 6 months frequency or percent,the time to achieve clear or almost clear of seborrheic dermatitis 1 months mean